Controversy Surrounding FDA Approval of Vioxx

Exploring the approval process of the drug Vioxx by the FDA and the subsequent revelations of heart problems associated with it post-approval. The chapter delves into the questionable decisions of the safety panel overseeing the study, the conflict of interest within the panel, and the delayed withdrawal of Vioxx from the market despite known risks. Dr. David Graham's whistleblowing on FDA's actions, the pharmaceutical industry's influence, and the transition to discussing the impact of Oxycodone are also highlighted.